Rallybio Corp
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| FOR THE YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Revenue: | ||
| Collaboration and license revenue | $858 | $636 |
| Total revenue | 858 | 636 |
| Operating expenses: | ||
| Research and development | 19,597 | 41,507 |
| General and administrative | 14,325 | 19,625 |
| Total operating expenses | 33,922 | 61,132 |
| Loss from operations | (33,064) | (60,496) |
| Other income: | ||
| Interest income | 2,189 | 4,216 |
| Gain on sale of joint venture and other income | 22,771 | 744 |
| Total other income, net | 24,960 | 4,960 |
| Loss before equity in losses of joint venture | (8,104) | (55,536) |
| Loss on investment in joint venture | 874 | 2,239 |
| Net loss | $(8,978) | $(57,775) |
| Net loss per common share, basic and diluted | $(1.59) | $(10.61) |
| Weighted-average common shares outstanding, basic and diluted | 5,629,370 | 5,443,332 |
| Other comprehensive (loss) gain: | ||
| Net unrealized (loss) gain on marketable securities | (50) | 53 |
| Other comprehensive (loss) gain | (50) | 53 |
| Comprehensive loss | $(9,028) | $(57,722) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.